EURACTIV PR

An easy way of publishing your relevant EU press releases.

Report identifies 9 key ingredients to improve access to medicines in the hospital setting

Date

08 Oct 2019

Sections

Health & Consumers
Many European countries are grappling with the efficiency of hospital care, which is facing growing demands from an increasingly elderly population. The optimal use of generic, biosimilar and value added medicines is one major contributor to this efficiency.
 
A new report by KPMG launched today titled ‘Improving healthcare delivery in hospitals by optimized utilization of medicines’ analyses the financing and procurement of medicines in hospitals in 8 European countries. The report outlines the enablers and barriers for increased use of generic, biosimilar and value added medicines in hospitals, and proposes 9 key ingredients to improve access to medicines in the hospital setting. Recommendations cover switching towards a most economically advantageous procedure (MEAT) criteria, awarding tenders to multiple winners whenever applicable and swiftly reopening tender procedures after the entry of the first multi-source medicine. More information on the key ingredients here.
 
Medicines for Europe Director General, Adrian van den Hoven said: “Hospitals account for the greatest share of care expenditure in EU health provision and are under pressure to deliver for an increasingly elderly population. This report shows that hospitals are missing a major opportunity to benefit from the optimal use of generic, biosimilar and value added medicines and implementing the 9 recommendations is key.”
 
About Medicines for Europe
Medicines for Europe represents the generic, biosimilar and value added medicines industries across Europe. Its vision is to provide sustainable access to high quality medicines, based on 5 important pillars: patients, quality, value, sustainability and partnership. Its members directly employ 190,000 people at over 400 manufacturing and 126 R&D sites in Europe, and invest up to 17% of their turnover in R&D investment. Medicines for Europe member companies across Europe are both increasing access to medicines and driving improved health outcomes. They play a key role in creating sustainable European healthcare systems by continuing to provide high quality, effective generic medicines, whilst also innovating to create new biosimilar medicines and bringing to market value added medicines, which deliver better health outcomes, greater efficiency and/or improved safety in the hospital setting for patients.
 
For more information please follow us at www.medicinesforeurope.com and on Twitter @medicinesforEU. 
 
Medicines for Europe Communications:Kate O Regan koregan@medicinesforeurope.com

Jobs

RussianTutoring.com
Online Russian Tutors
ECPC - European Cancer Patient Coalition
Legal Expert
IUCN EUROPEAN REGIONAL OFFICE
Finance Officer
European Parliament
Parlamentarische*r Assisstent*in
OCTA: Association of Overseas Countries and Territories of the European Union
Coordinator of OCTA Secretariat
European Cyclists' Federation asbl
Intern Administration